Thermobalancing therapy with Dr Allen’s Device treats chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) effectively and safely, helping to prevent the development of benign prostatic hyperplasia (BPH), also known as benign prostate enlargement (BPE).
Non-invasive Dr Allen’s Device provides a clinically proven treatment that relieves pelvic pain, reduces the size of inflamed prostate gland and helps to prevent its enlargement.
OXFORD, UK / ACCESSWIRE / August 2, 2024 / Medical innovation discussions held during the latest LSX World Congress in London highlighted the necessity of adopting more out-of-hospital treatments, such as Thermobalancing therapy, increasing patient safety. New clinical research has confirmed high effectiveness and total safety of Thermobalancing therapy and wearable Dr Allen’s Devices in relieving pain in patients with chronic prostatitis. More importantly, this non-surgical treatment with Dr Allen’s Device is world’s first to enable the prevention of prostate enlargement, a widespread ageing health condition known as benign prostatic hyperplasia (BPH).
A recent scientific article, “Association between chronic prostatitis and subsequent benign prostatic hyperplasia: a population-based national cohort study,” highlights a critical role of prostatitis in the development of BPH. It is therefore particularly important that the effect of Thermobalancing medical technology on chronic prostatitis becomes a powerful preventative measure against the development of enlarged prostate gland (BPH). Over 50% of men in their 50s have troubling symptoms of BPH, and many more men are inevitably affected by BPH with age.
New clinical trial results on Dr Allen’s Device discussed at the LSX World Congress 2024
“The use of Dr Allen’s Device for treating chronic prostatitis has showed its unique effectiveness in achieving a full recovery in most patients,” says the Co-Founder of Fine Treatment Ariana Adjani, which describing their medtech innovation. “Several clinical studies show remarkable effectiveness of Thermobalancing therapy with Dr Allen’s Device in treating both chronic prostatitis with pelvic pain, and prostate enlargement. Our wearable Dr Allen’s Device is non-invasive and, thus, provides a totally safe treatment, which can be easily used at home.”
The essence of effectiveness of chronic prostatitis and BPH treatment with Dr Allen’s Device is revealed in a medical article, titled “Innovative Thermobalancing therapy and Dr Allen’s Device for the first time employ body energy to treat chronic prostatic diseases effectively“, published in the International Journal of Quality Innovation. Significant relief of troubling symptoms and a major improvement in the quality of life of patients have been evident in all clinical studies on Dr Allen’s Device independently conducted by different medical teams.
Risky treatments for chronic prostatitis and BPH
All drugs for CP/CPPS and BPH are found to be risky:
α1-blockers group are associated with multiple adverse reactions, such as abnormal ejaculation, postural hypotension, dizziness, asthenia, and other problems.
5α-reductase inhibitors (5-ARIs) decrease libido and cause gynecomastia, erectile dysfunction, sexual side effects and anxiety, depression, and more new health problems.
Leading urological associations are banning all types of prostate surgery in men with chronic prostatitis due to poor results and terrible side effects. However, BPH surgery is still widely used. Some people believe that men aged 50 and older regard normal sexual function as unnecessary for their wellbeing. It goes in sharp contrast with what most men in this age group feel, and who often end up suffering in silence because of prostate surgeries.
It should be noted that chronic prostatitis and prostate enlargement (BPH) are non-cancerous chronic health conditions that typically do not require urgent surgery. It is therefore possible to opt for a non-invasive approach with Dr Allen’s Device.
What you should know about chronic prostatitis and prostate enlargement:
Chronic prostatitis (CP/CPPS) and prostate enlargement (BPH or BPE) are non-life-threatening conditions. Therefore, they must be treated safely and non-invasively in the first place.
The prostate gland surrounds the urethra at the neck of the bladder. An inflamed or enlarged prostate gland presses against and pinches the urethra. This causes various urination problems that require attention and treatment.
Chronic prostate conditions are very common. For instance, the risk of having BPH increases as men get older and it affects over 90% of men aged 80 and over.
CP/CPPS and BPH drugs are risky. They do not treat the affected prostate gland itself but try to relieve the symptoms and can lead to new health problems in the long-term.
Thermobalancing therapy improves blood circulation in the prostate gland targeting the cause of CP/CPPS and BPH and terminating the progression of these conditions.
Wearable Allen’s Device provides a unique treatment for chronic prostate diseases
The USPTO-patented Thermobalancing therapy with Dr Allen’s Device is the world’s first treatment that harnesses the body’s own heat while naturally treating chronic pelvic pain improving patients’ wellbeing.
Wearable Dr Allen’s Device can be used to treat chronic prostatitis at home and prevent the development of prostate enlargement. Natural Thermobalancing therapy can help to avoid many troubling health problems associated with inflamed and enlarged prostate gland, and significantly improve the lives of patients and their family members.
Contact Information:
Alex Day
Customer Service Manager
Fine Treatment
Oxford, United Kingdom
Tel.: +447958878300
Email: info@finetreatment.com
www.finetreatment.com
SOURCE: Fine Treatment
View the original press release on accesswire.com
AmeriGuard Security Services, Inc. Transportation platform TransportUS, Inc., expands services with an additional new contract…
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Inc. revealed today that IDEOlogy Health is No. 717…
BOSTON, MA / ACCESSWIRE / August 13, 2024 / Colorectal cancer, a serious condition affecting…
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC PINK:…
With Three-Year Revenue Growth of 233 Percent, ActivTrak Ranks No. 2335 Among America's Fastest-Growing Private…
iReferral® automatically identifies potential organ and tissue donors and streamlines the hospital-to-OPO referral process. ANN…